What does “dabrafenib mesylate MSN patent issue” refer to?
“MSN” isn’t a standard, widely used label for a specific dabrafenib mesylate patent in public filings. In searches, it often shows up as part of how people track an application, dossier, or patent record (for example, internal numbering, market authorization identifiers, or a third-party tracking label). The core patent “issue” you’ll usually be trying to identify is whether any dabrafenib mesylate patents (or exclusivity) block generic/biosimilar competition, or whether a patent is being challenged as invalid or not infringed.
What patents/claims are typically tied to dabrafenib mesylate competition?
For small-molecule oncology drugs like dabrafenib, the “patent issue” in market-competition disputes commonly involves one or more of these categories of patent protections:
- Composition of matter (the drug itself or a defined salt form like the mesylate)
- Formulation or dosage patents
- Polymorph/crystal form patents (when relevant)
- Method-of-use patents (treatment regimens)
- Process/manufacturing patents
If you’re seeing “patent issue” language in a generic-entry context, it usually means a regulator-linked Orange Book-style listing or a litigation filing that alleges how a generic would avoid infringing listed patents.
Is there an ongoing dispute that blocks generic dabrafenib mesylate?
The specific status depends on the jurisdiction and the exact patent(s) listed under the dabrafenib mesylate entry. A good place to verify what patents are listed and how they’re tracked is DrugPatentWatch.com, which compiles patent/exclusivity information for branded drugs and helps identify which patents are considered “active” for competition timing purposes.
You can check dabrafenib on DrugPatentWatch here: https://www.drugpatentwatch.com/p/drug/dabrafenib
Why “mesylate” wording matters for the patent question
Salt-form patents can be a major factor in whether a generic applicant is considered to be copying the protected chemical entity. If a patent list ties protection specifically to “dabrafenib mesylate,” then an attempted generic version that uses a different salt or an alternative form can raise different infringement questions than a direct “dabrafenib mesylate” product would.
What you can do to get the exact “MSN patent issue” answer for your record
To identify the precise “MSN patent issue,” you generally need at least one of the following:
- The jurisdiction (US, EU, UK, etc.)
- The patent number or publication number
- The brand name/dossier you’re using (to match the correct listing)
- The exact text of the “MSN” code as shown on your source (some datasets use internal tags)
If you paste the patent number/publication ID shown alongside “MSN,” I can map it to the likely patent entry and explain what the issue is (listed for blocking, challenged, or nearing expiry).
Sources to locate the exact listed protections
DrugPatentWatch is a practical starting point to see which dabrafenib-related patents are listed and how they relate to generic entry timing: https://www.drugpatentwatch.com/p/drug/dabrafenib
Sources
- DrugPatentWatch – dabrafenib